TriangleNCT02366143 · OUTCOME
Percentage of Participants With Adverse Events
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage
- Interval / dispersion
- Not reported
- Time frame
- Baseline up to data cutoff date 7 December 2020 (up to approximately 68 months)
What was measured
Percentage of participants with at least one adverse event.
Analysis population: Safety population included all treated patients, defined as randomized patients who received any amount of any component of study treatment.
Groups in this outcome
Arm C (Bevacizumab+Paclitaxel+Carboplatin)
Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)
Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
Arm A (Atezolizumab+Paclitaxel+Carboplatin)
Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
| Group | Source count |
|---|---|
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 394 |
| Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 393 |
| Arm A (Atezolizumab+Paclitaxel+Carboplatin) | 400 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm C (Bevacizumab+Paclitaxel+Carboplatin) | 99.0 | Not reported | Not reported | Not reported | Not reported |
| Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) | 98.2 | Not reported | Not reported | Not reported | Not reported |
| Arm A (Atezolizumab+Paclitaxel+Carboplatin) | 97.8 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 99.0
- group Id
- OG001
- value
- 98.2
- group Id
- OG002
- value
- 97.8
- denoms
- counts
- group Id
- OG000
- value
- 394
- group Id
- OG001
- value
- 393
- group Id
- OG002
- value
- 400
- units
- Participants
- description
- Percentage of participants with at least one adverse event.
- groups
- description
- Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
- id
- OG000
- title
- Arm C (Bevacizumab+Paclitaxel+Carboplatin)
- description
- Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
- id
- OG001
- title
- Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)
- description
- Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
- id
- OG002
- title
- Arm A (Atezolizumab+Paclitaxel+Carboplatin)
- param Type
- NUMBER
- population Description
- Safety population included all treated patients, defined as randomized patients who received any amount of any component of study treatment.
- reporting Status
- POSTED
- time Frame
- Baseline up to data cutoff date 7 December 2020 (up to approximately 68 months)
- title
- Percentage of Participants With Adverse Events
- type
- SECONDARY
- unit Of Measure
- Percentage
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice